Orion Oyj (OTCMKTS:ORINY) Shares Down 0.1% - Time to Sell?

Orion Oyj (OTCMKTS:ORINY - Get Free Report) shares were down 0.1% on Wednesday . The company traded as low as $33.01 and last traded at $33.01. Approximately 126 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 2,262 shares. The stock had previously closed at $33.03.

Wall Street Analysts Forecast Growth

Separately, Nordea Equity Research downgraded shares of Orion Oyj to a "hold" rating in a research note on Tuesday, February 4th.

Orion Oyj Stock Performance

The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.41 and a current ratio of 2.42. The firm's fifty day simple moving average is $30.11 and its 200-day simple moving average is $27.03. The stock has a market cap of $9.46 billion, a P/E ratio of 26.60 and a beta of 0.17.

Orion Oyj (OTCMKTS:ORINY - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The company reported $0.23 earnings per share for the quarter. The company had revenue of $373.03 million during the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. Equities research analysts expect that Orion Oyj will post 1.18 EPS for the current fiscal year.

Orion Oyj Increases Dividend

The firm also recently declared a dividend, which was paid on Tuesday, April 29th. Investors of record on Monday, April 7th were given a $0.4478 dividend. The ex-dividend date of this dividend was Monday, April 7th. This is an increase from Orion Oyj's previous dividend of $0.24. Orion Oyj's dividend payout ratio (DPR) is presently 24.43%.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.